<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04432090</url>
  </required_header>
  <id_info>
    <org_study_id>1552172</org_study_id>
    <nct_id>NCT04432090</nct_id>
  </id_info>
  <brief_title>Study of the Pharmacologic Action of a GPR119 Agonist on Glucagon Counter-regulation During Insulin-induced Hypoglycemia in Type 1 Diabetes Mellitus</brief_title>
  <acronym>PHROG</acronym>
  <official_title>A Randomized, Placebo-controlled, Double-blinded Cross-over Study of the Pharmacologic Action of a GPR119 Agonist on Glucagon Counter-regulation During Insulin-induced Hypoglycemia in Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test if a specific research medication could increase the
      response to low blood glucose in people with type 1 diabetes. The response of the body to low
      blood sugar will be measured in healthy people as a reference point.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal glucagon concentration during hypoglycemia</measure>
    <time_frame>Day 14, Day 28, 6 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Volunteers with Type 1 diabetes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous glucose monitoring (CGM)</intervention_name>
    <description>The CGM that will be provided with is a Dexcom Continuous Glucose Monitoring System. Participant will wear CGM for the duration of the study and will return the CGM at the end of the study. The CGM will be blinded which means the sugar levels monitored through the CGM will not be visible to the participant. However, CGM data will be periodically reviewed with participant.</description>
    <arm_group_label>Volunteers with Type 1 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard mixed meal challenge</intervention_name>
    <description>We will measure how the body responds to a meal while taking the study medication. Blood samples will be obtained throughout the test. To make the blood sampling easier, an intravenous plastic tubes (called IV) will be placed in the vein of participant arm with a needle. The IV will be kept in place during the test and overnight. Participants will be given a meal with pre-specified nutrients. Participants with diabetes will inject the appropriate amount of insulin based on their ratios as they would normally do. Participants will take the study medication 30 minutes after the meal (T1DM participants only). Venous blood will be drawn from the IV before the meal and every 30 minutes during the three and a half hours following the meal to measure the production of insulin, glucagon, other hormones and study medication levels.</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Volunteers with Type 1 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperinsulinemic euglycemic-hypoglycemic clamp</intervention_name>
    <description>Glucose is &quot;clamped&quot;, or held, at a certain level so that we can see how the body responds to low blood sugar. For the &quot;euglycemic&quot; part of the clamp, participant will receive a chemically modified glucose called a stable isotope through the IV. About two and a half hours later, they will receive both insulin and glucose with the goal to keep blood glucose levels at approximately 85 mg/dl. For the &quot;hypoglycemic&quot; part of the clamp, we will gradually lower participants blood glucose level over about 30 minutes</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Volunteers with Type 1 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Volunteers with Type 1 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Study Medication (MBX-2982)</intervention_name>
    <description>Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Volunteers with Type 1 diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Type 1 diabetes cohort

          1. Age &gt;20 years

          2. Diagnosis of T1DM according to American Diabetes Association (ADA) criteria
             continuously requiring insulin for survival

          3. Diabetes diagnosis performed more than 5 years before enrollment

          4. Fasting C-peptide levels &lt; 0.7 ng/mL with a concurrent plasma glucose concentration &gt;
             90 mg/dL

          5. For female participants: agrees not to become pregnant during the study and for at
             least 2 weeks after the last dose of the study medication. For male participants:
             agrees not to donate sperm or not to get a woman pregnant during the study and for at
             least 2 weeks after the last dose of the study medication.

        Healthy subject cohort

          1. Age &gt;20 years

          2. General good health

          3. Creatinine clearance &gt;80 mL/min based on MDRD equation

          4. Fasting blood glucose (FBG) &gt;70 mg/dL and &lt;100 mg/dL

          5. No history of diabetes

        Exclusion Criteria:

          1. BMI &gt;30 kg/m2 and &lt;18.5 kg/m2

          2. No evidence by history, EKG or exams of symptomatic cardiovascular disease (unstable
             angina, myocardial infarction or coronary revascularization within 6 months,
             clinically significant abnormalities on EKG, presence of cardiac pacemaker, implanted
             cardiac defibrillator)

          3. Evidence of autonomic neuropathy

          4. Liver disease (AST or ALT &gt;2.5 times the upper limit of normal)

          5. Kidney disease (creatinine &gt;1.6 mg/dl or estimated GFR &lt;60 ml/min).

          6. Dyslipidemia, including triglycerides &gt;500 mg/dl, LDL &gt;200 mg/dl or unstable
             hyperlipidemia. Treatment with a single lipid lowering agents is allowed if stable
             within the previous 3 months.

          7. Anemia (hemoglobin &lt;12 g/dl in men, &lt;11 g/dl in women)

          8. Thyroid dysfunction (suppressed thyroid stimulating hormone (TSH), elevated TSH &lt;10
             µIU/ml if symptomatic or elevated TSH &gt;10 µIU/ml if asymptomatic)

          9. Uncontrolled hypertension (BP &gt;160 mmHg systolic or &gt;100 mmHg diastolic) or treatment
             with more than 2 antihypertensive medications

         10. History of cancer within the last 5 years (skin cancers, with the exception of
             melanoma, may be acceptable).

         11. History of organ transplant

         12. History of HIV, active Hepatitis B or C, or Tuberculosis

         13. Pregnancy, lactation or 6 months postpartum from the scheduled date of collection

         14. Females of childbearing potential (any female except those with tubal ligation,
             hysterectomy, or absence of menses &gt;2 years) unwilling to use an approved method of
             contraception (one medically accepted method of contraception with ≥99% effectiveness
             when used consistently and correctly: implantable uterine device (IUD), hormonal
             contraception). Male participants: unwilling to use appropriate contraception (e.g.
             condoms) and/or their partner uses a medically accepted form of contraception during
             the study.

         15. History of Major Depression in the last 5 years

         16. History of an eating disorder

         17. History of bariatric surgery

         18. History of drug or alcohol abuse (&gt; 3 drinks per day) within the last 5 years

         19. Psychiatric disease prohibiting adherence to study protocol

         20. Use of oral or injectable anti-hyperglycemic agents: metformin, sulfonylureas, DPP IV
             inhibitors, SGLT-2 inhibitors, thiazolidinediones, acarbose, GLP-1 analogs

         21. Current use of beta-adrenergic blocking agents or their use was stopped less than one
             month before recruitment

         22. Initiation or change in hormone replacement therapy within the past 3 months
             (including, but not limited to thyroid hormone or estrogen replacement therapy)

         23. Use of any medications known to influence glucose, fat and/or energy metabolism within
             the last 3 months (e.g., growth hormone therapy, glucocorticoids [steroids],
             prescribed medications for weight loss, etc.)

         24. Current night shift worker

         25. Presence of any condition that, in the opinion of the Investigator, compromises
             participant safety or data integrity or the participant's ability to complete study
             visits Additional exclusion Criteria for type 1 diabetes cohort

         26. History of T2DM or any form of diabetes other than T1DM

         27. Hypoglycemia unawareness as assessed using the GOLD score

         28. Using a predictive low blood glucose suspend mode on an insulin pump or a hybrid
             closed loop algorithm for insulin delivery. For those applying these strategies for
             everyday management of blood glucose and willing to participate, the algorithm will be
             stopped at enrollment where possible.

         29. Two or more episode of severe hypoglycemia per month in the past six months.

         30. QTcF &gt;450 ms for males and &gt;470 ms for females

         31. Using non-insulin agents to control blood glucose levels.

         32. No evidence of moderate or severe end-organ diabetic complications of retinopathy,
             nephropathy or neuropathy. Non-proliferative retinopathy and microalbuminura will be
             allowed.

             Additional exclusion Criteria for the healthy cohort

         33. Insulin treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Pratley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruitment Department</last_name>
    <phone>407-303-7100</phone>
    <email>Fh.tri.recruitment@adventhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AdventHealth Translational Research Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Recruitment Department</last_name>
      <phone>407-303-7100</phone>
      <email>Fh.tri.recruitment@adventhealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ekberg JH, Hauge M, Kristensen LV, Madsen AN, Engelstoft MS, Husted AS, Sichlau R, Egerod KL, Timshel P, Kowalski TJ, Gribble FM, Reiman F, Hansen HS, Howard AD, Holst B, Schwartz TW. GPR119, a Major Enteroendocrine Sensor of Dietary Triglyceride Metabolites Coacting in Synergy With FFA1 (GPR40). Endocrinology. 2016 Dec;157(12):4561-4569. Epub 2016 Oct 25.</citation>
    <PMID>27779915</PMID>
  </reference>
  <reference>
    <citation>Flock G, Holland D, Seino Y, Drucker DJ. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. Endocrinology. 2011 Feb;152(2):374-83. doi: 10.1210/en.2010-1047. Epub 2010 Nov 10.</citation>
    <PMID>21068156</PMID>
  </reference>
  <reference>
    <citation>Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes. 2009 May;58(5):1058-66. doi: 10.2337/db08-1237. Epub 2009 Feb 10.</citation>
    <PMID>19208912</PMID>
  </reference>
  <reference>
    <citation>Li NX, Brown S, Kowalski T, Wu M, Yang L, Dai G, Petrov A, Ding Y, Dlugos T, Wood HB, Wang L, Erion M, Sherwin R, Kelley DE. GPR119 Agonism Increases Glucagon Secretion During Insulin-Induced Hypoglycemia. Diabetes. 2018 Jul;67(7):1401-1413. doi: 10.2337/db18-0031. Epub 2018 Apr 18.</citation>
    <PMID>29669745</PMID>
  </reference>
  <reference>
    <citation>Segerstolpe Å, Palasantza A, Eliasson P, Andersson EM, Andréasson AC, Sun X, Picelli S, Sabirsh A, Clausen M, Bjursell MK, Smith DM, Kasper M, Ämmälä C, Sandberg R. Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes. Cell Metab. 2016 Oct 11;24(4):593-607. doi: 10.1016/j.cmet.2016.08.020. Epub 2016 Sep 22.</citation>
    <PMID>27667667</PMID>
  </reference>
  <reference>
    <citation>Bolli G, Calabrese G, De Feo P, Compagnucci P, Zega G, Angeletti G, Cartechini MG, Santeusanio F, Brunetti P. Lack of glucagon response in glucose counter-regulation in type 1 (insulin-dependent) diabetics: absence of recovery after prolonged optimal insulin therapy. Diabetologia. 1982 Feb;22(2):100-5.</citation>
    <PMID>7037510</PMID>
  </reference>
  <reference>
    <citation>Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science. 1973 Oct 12;182(4108):171-3.</citation>
    <PMID>4581053</PMID>
  </reference>
  <reference>
    <citation>Gerich JE. Lilly lecture 1988. Glucose counterregulation and its impact on diabetes mellitus. Diabetes. 1988 Dec;37(12):1608-17. Review.</citation>
    <PMID>3056759</PMID>
  </reference>
  <reference>
    <citation>Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1997 Feb;46(2):271-86.</citation>
    <PMID>9000705</PMID>
  </reference>
  <reference>
    <citation>Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol. 2014 Dec;10(12):711-22. doi: 10.1038/nrendo.2014.170. Epub 2014 Oct 7. Review.</citation>
    <PMID>25287289</PMID>
  </reference>
  <reference>
    <citation>UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007 Jun;50(6):1140-7. Epub 2007 Apr 6.</citation>
    <PMID>17415551</PMID>
  </reference>
  <reference>
    <citation>Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013 Jul 25;369(4):362-72. doi: 10.1056/NEJMra1215228. Review.</citation>
    <PMID>23883381</PMID>
  </reference>
  <reference>
    <citation>Rizza RA, Cryer PE, Gerich JE. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest. 1979 Jul;64(1):62-71.</citation>
    <PMID>36413</PMID>
  </reference>
  <reference>
    <citation>Yue JT, Burdett E, Coy DH, Giacca A, Efendic S, Vranic M. Somatostatin receptor type 2 antagonism improves glucagon and corticosterone counterregulatory responses to hypoglycemia in streptozotocin-induced diabetic rats. Diabetes. 2012 Jan;61(1):197-207. doi: 10.2337/db11-0690. Epub 2011 Nov 21.</citation>
    <PMID>22106159</PMID>
  </reference>
  <reference>
    <citation>Szewczyk JW, Acton J, Adams AD, Chicchi G, Freeman S, Howard AD, Huang Y, Li C, Meinke PT, Mosely R, Murphy E, Samuel R, Santini C, Yang M, Zhang Y, Zhao K, Wood HB. Design of potent and selective GPR119 agonists for type II diabetes. Bioorg Med Chem Lett. 2011 May 1;21(9):2665-9. doi: 10.1016/j.bmcl.2010.12.086. Epub 2010 Dec 22.</citation>
    <PMID>21273063</PMID>
  </reference>
  <reference>
    <citation>Christensen M, Calanna S, Sparre-Ulrich AH, Kristensen PL, Rosenkilde MM, Faber J, Purrello F, van Hall G, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. Diabetes. 2015 Jan;64(1):72-8. doi: 10.2337/db14-0440. Epub 2014 Jul 22.</citation>
    <PMID>25053587</PMID>
  </reference>
  <reference>
    <citation>Davis SN, Mann S, Briscoe VJ, Ertl AC, Tate DB. Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes. Diabetes. 2009 Mar;58(3):701-9. doi: 10.2337/db08-1230. Epub 2008 Dec 10.</citation>
    <PMID>19073776</PMID>
  </reference>
  <reference>
    <citation>Farngren J, Persson M, Schweizer A, Foley JE, Ahrén B. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab. 2012 Oct;97(10):3799-806. doi: 10.1210/jc.2012-2332. Epub 2012 Aug 1.</citation>
    <PMID>22855332</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

